Solution structure of the Equine Infectious Anemia Virus p9 protein: a rationalization of its different ALIX binding requirements compared to the analogous HIV-p6 protein
- Alok Sharma†1, 2,
- Karsten Bruns†1, 2,
- René Röder2, 3,
- Peter Henklein3,
- Jörg Votteler2,
- Victor Wray1Email author and
- Ulrich Schubert2
© Sharma et al; licensee BioMed Central Ltd. 2009
Received: 2 June 2009
Accepted: 17 December 2009
Published: 17 December 2009
The equine infection anemia virus (EIAV) p9 Gag protein contains the late (L-) domain required for efficient virus release of nascent virions from the cell membrane of infected cell.
In the present study the p9 protein and N- and C-terminal fragments (residues 1-21 and 22-51, respectively) were chemically synthesized and used for structural analyses. Circular dichroism and 1H-NMR spectroscopy provide the first molecular insight into the secondary structure and folding of this 51-amino acid protein under different solution conditions. Qualitative 1H-chemical shift and NOE data indicate that in a pure aqueous environment p9 favors an unstructured state. In its most structured state under hydrophobic conditions, p9 adopts a stable helical structure within the C-terminus. Quantitative NOE data further revealed that this α-helix extends from Ser-27 to Ser-48, while the N-terminal residues remain unstructured. The structural elements identified for p9 differ substantially from that of the functional homologous HIV-1 p6 protein.
These structural differences are discussed in the context of the different types of L-domains regulating distinct cellular pathways in virus budding. EIAV p9 mediates virus release by recruiting the ALG2-interacting protein X (ALIX) via the YPDL-motif to the site of virus budding, the counterpart of the YPXnL-motif found in p6. However, p6 contains an additional PTAP L-domain that promotes HIV-1 release by binding to the tumor susceptibility gene 101 (Tsg101). The notion that structures found in p9 differ form that of p6 further support the idea that different mechanisms regulate binding of ALIX to primary versus secondary L-domains types.
Equine infectious anemia virus (EIAV) is a retrovirus of the lentivirus subfamily which also includes HIV-1, HIV-2 and simian immunodeficiency viruses (SIVs). Compared to the primate lentiviruses the EIAV genome is the smallest (~8.2 kb) and genetically simplest as it contains only three accessory genes (rev, tat, and S2) in addition to the canonical retroviral elements gag, pol, and env. As with other retroviruses the Gag polyprotein Pr55 of EIAV is required and sufficient for assembly and budding of virus like particles. The cleavage of the Pr55 Gag-precursor by the virus-encoded protease thereby yields the four major internal structural proteins: the matrix (MA, p15), capsid (CA, p26), nucleocapsid (NC, p11), and p9 proteins [1, 2]. The Gag proteins are synthesized in the cytoplasm and targeted to the plasma membrane where they assemble into immature budding particles that consist predominantly of uncleaved polyproteins and are released from the cell membrane . Maturation of the EIAV particle occurs concurrently with or shortly after release of the progeny virion in concert with protease activation.
The genomic position of p9 is analogous to that of the HIV-1 p6 protein and other similar proteins from different lentiviruses. Compared to HIV-1 p6, EIAV p9 has only minimal amino acid sequence homology and a considerable variation in the predicted secondary structure. Besides the function of p9 in viral DNA production and processing of the provirus , p9 plays, like p6 of HIV-1, an essential role in virus release, which are governed by late assembly domains (L-domains). Proline-rich L-domains, such as PTAP and PPPY have been identified in HIV-1, Rous sarcoma virus (RSV), and a variety of other enveloped viruses [5–7]. The HIV-1 PTAP motif specifically interacts with the N-terminus of the tumor susceptibility gene 101 (Tsg101), a component of the host endosomal sorting complex required for transport I (ESCRT I), a system that regulates membrane fission during multivesicular body (MVB) formation and cytokinesis [8–12]. Interestingly, the EIAV YPDL L-domain motif has been shown to interact with two cellular proteins, the ALG-2-interacting-protein-X (ALIX/AIP1; ALIX is used hereafter) [7, 10] and the μ2 subunit of the AP-2 adaptor protein complex .
Although L-domains appear to interact with different cellular proteins, a certain functional interchangeability has been reported. For example, both PTAP and PPPY motifs can substitute for the YPDL domain to support EIAV replication . These observations indicate that retroviruses, along with other enveloped viruses, have evolved different L-domains to specifically exploit certain host cellular machineries for virus budding and release.
Recently, we have characterized the structure of the HIV-1 p6 protein , and others have studied the structure of p6 fragments in complex with binding partners Tsg101 and ALIX [16, 17]. Among known lentiviruses, the 51-amino acid EIAV p9 protein is one of the smallest proteins and the molecular structure has not been defined hitherto. With the goal of understanding the molecular mechanism involved in the biological function of p9, we have explored the high resolution structure and folding of p9, derived from the EIAVWYOMING isolate, under various solution conditions. Although the molecule exhibits a high degree of flexibility in a pure aqueous environment it adopts α-helical structures in an hydrophobic environment simulated by organic solvents. According to high resolution NMR data, p9 consists of two independent structural domains, an unstructured N-terminus and an extended C-terminal helix. The structure of p9 was compared with that of HIV-1 p6, and their similarities and differences are discussed in terms of differences in their L-domain functions.
Synthesis and purification of synthetic p9 (sp9)
The s p9 molecule (s p91-51) and its fragments (s p91-21 and s p922-51) were chemically synthesized using solid-phase peptide synthesis (SPPS) and purified to homogeneity. The specific procedure, established previously by us for the HIV-1 p6 protein  with respect to the use of coupling agents, protection groups, cleavage reagents, and duration of coupling reactions, gave reproducibly high yields (usually 15%) of purified s p91-51. It avoided problems normally encountered in such syntheses that include incomplete deprotection and coupling, inter- and intra-chain reaction with the resin matrix, side chain reactions, and peptide aggregation.
Predicted structural details of EIAV p9
Secondary structure prediction for p9 using public domain semi-empirical programs
C-terminus contributes to p9 secondary structure
A first insight into the secondary structure and folding of s p91-51 and its fragments thereof was obtained by analysis of the peptides at ambient temperature under various solution conditions by circular dichroism (CD) spectroscopy. We simulated a hydrophobic environment by using the organic solvent trifluoroethanol (TFE) to assess the degree of secondary structure under hydrophobic conditions. TFE is chosen for its well known characteristics as it favors intramolecular interactions and stabilizes secondary structure, particularly α-helices in domains of a peptide that have a propensity for such secondary structure . As TFE tends to disrupt quaternary structure and dissociate peptide aggregates, it can alleviate problems occurring with intermolecular interactions in the higher concentration ranges required for NMR investigations and provide a platform to perform CD and NMR studies under similar solution conditions.
Structural statistics for the 20 final structures of s p922-51 in 50% TFE
No. of distance constrains
Intraresidual (|i-j| = 0)
Sequential (|i-j| = 1)
Medium range (|i-j| ≤ 4)
Average number of NOE violations ≥ 0.2°A
Mean energies (kj/mol)
E van der Walls
Ebond + Eangle + Eimpropers
% residues with φ, ψ in most favourable regions
% residues with φ, ψ in additionally allowed regions
% residues with φ, ψ in generally allowed regions
% residues with φ, ψ in disallowed regions
Identification of structural elements in sp91-21, sp922-51, and sp91-51 by 1H NMR spectroscopy
In order to define in more detail the position of secondary structure identified by CD spectroscopy, we have recorded 1H NMR spectra of full length s p91-51 and the N- and C-terminal fragments s p91-21 and s p922-51 dissolved in 50% aqueous TFE-d2. Initially, we have analyzed the structural characteristics of the peptides on the basis of 1Hα chemical shift data, which correlate with the chemical environment of the respective amino acid residues and therefore have proven to be useful for determining the presence, nature and exact position of secondary structure elements in such molecules . For instance, a minimum of four adjacent residues, showing pronounced upfield shifts relative to random coil values (< -0.1 ppm) indicate local helical structure while downfield shifts (> 0.1 ppm) of three or more adjacent residues are indicative of α-helical structures. In order to obtain these data a set of one- and two-dimensional (1D, 2D) 1H NMR spectra was recorded for each peptide. Signal assignments of the NMR spectra were accomplished using a standard procedure combining homonuclear 2D TOCSY and 2D NOESY NMR spectral data . Individual spin systems were identified from 2D TOCSY spectra, starting from the backbone amide protons. Sequence-specific assignments were determined from cross-peaks in the 2D NOESY spectra based on short observable distances between 1HN, 1Hα and 1Hβ nuclei of amino acid residue i and 1HN of residue i+1. Spin systems that could readily be recognized were used as starting points to establish residue positions in the peptide sequence.
Unlike the N-terminus, the C-terminal region shows a large number of upfield shifts comprising residues Ser-27 to Leu-49 and therefore is clearly indicative of the presence of helical structure in this section of the molecule (Fig. 4B and 4C). Even though residues Glu-28 and Glu-42 exhibit upfield shifts of only - 0.042 and - 0.079, respectively, it seems most likely that they are both part of a continuous helix, which in the case of Glu-28 becomes evident by the presence of very pronounced upfield shifts of the neighboring residues Ser-27 and Ile-29, and in the case of Glu-42 by a further stretch of seven weakly helical residues located directly to the C-terminal side of Glu-42. However, as the upfield shifts of these residues (Glu-42/Asp-43 to Leu-49) are distinctly less pronounced we assume that this part of the helix possesses decreased stability. At its N-terminus the helix is delimited by Pro-24, a residue that is often considered to be a helix-breaker.
A comparison of the 1Hα chemical shift differences of the full length molecule with those of the two fragments reveals that they are almost identical apart from residues Leu-22 to Leu-26. This observation can easily be explained with the fact that this site represents the interface of the two fragments and therefore the respective C- (s p91-21) or N-terminus (s p922-51) whereas it is the central region of full length s p9.
Structure calculations from quantitative NOE data
The problem observed above for the full length molecule was caused by the overlap of signals that could therefore not be unambiguously identified or accurately quantified in the 2D spectra. Most likely, this problem arose from the high proportion of similar amino acids in the p9 sequence (Asn/Asp, Gln/Glu and Leu/Ile) that are distributed throughout the molecule. As all the qualitative data indicate the sole structured region in the molecule is restricted to the C-terminal region we focused our attention on the C-terminal peptide. This resolved the problem of signal overlap and allowed identification of sufficient medium range NOEs for structure calculations.
Secondary structure of p9 is strongly dependent upon solution conditions
Previous studies have established p9 as the functional equivalent of the HIV-1 p6 protein, although these proteins of almost identical size have only limited sequence homology. Therefore, a comparison of the structural properties of these two analogous proteins is required to understand their structure-function relationships and their interactions with the same cellular factors such as ALIX. In water, p6 adopts a random coil conformation without any preference for secondary structure [15, 27] while in a hydrophobic environment specific regions, residues 14-18 (helix 1) and residues 35-44 (helix 2), of the molecule adopt helical structure . Helix 2 of HIV-1 p6 appears to be important for specific binding interactions with ALIX .
In the quest to establish the structural details of the EIAV p9 molecule, CD analysis of s p91-51 shows that the molecule has no significant or very little secondary structure when dissolved in pure water at pH 3 or in buffer at physiological pH 7.2. However, secondary structure is observed and clearly stabilized in the presence of increasing amounts (up to 50%) of TFE used to introduce a more hydrophobic environment that is assumed to more closely simulate in vivo conditions where p9 is exposed to the hydrophobic surfaces of other proteins. However, for s p91-51 maximum α-helical content was found at room temperature in 50% aqueous TFE at pH 3 that decreased upon changing the pH to 7.2, irrespective of the hydrophobic environment (Fig. 3A). The CD data for the N- and C-terminal fragments clearly indicate secondary structure formation in solution is restricted to the C-terminus of the molecule. This fragment also behaves in a similar manner to the full length molecule in that maximal structure is found in 50% TFE and is less stable at physiological pH (Fig. 3C).
As in our previous structural elucidation of HIV-1 p6 we completely assigned the 1D and 2D 1H NMR spectra of s p91-51, in conjunction with its N- and C-terminal fragments, to afford the position and nature of structured regions in the molecule. Well established criteria used previously by us, namely 1Hα chemical shifts, indicate in its most structured state s p9 shows one region with a propensity for α-helical structure in the C-terminal region of the protein extending from Leu-26/Ile-28 to Ser-48. According to the chemical shift differences in both the full-length s p9 and the shorter C-terminal peptide s p922-51 there is some indication that the structured region extends back to residue Leu-26. The smaller negative differences observed towards the C-terminus indicate a weakening of the helical interactions in this region. A probability analysis for helical or extended conformation of dipeptidic segments for a limited number of interproton distances in the full length molecule support this conclusion (Fig. 5). The C-terminal fragment exhibited 34.3% helical content in 50% TFE. In contrast to the C-terminal peptide there was no evidence of any structured region in the N-terminus either in the full length molecule or its N-terminal peptide. This was apparent even under the most favorable conditions (50% TFE at pH 3) independently from both the CD and NMR data.
Based on the above and the limited number of unambiguously assigned medium range NOEs caused by signal overlap of similar amino acid spin systems in s p91-51, structural calculations were undertaken of the C-terminal fragment s p922-51, which contains the L-domain and the only structured region of the molecule. The molecular dynamic calculations, using a total of 358 quantitative NOEs that included 137 sequential and 108 medium range NOEs, afford a central arrangement that confines the helical structure to the region between Glu-28 to Asp-47 (Fig. 7).
Comparison of the structure of EIAV p9 and HIV-1 p6
A considerable amount of literature now exists suggesting that EIAV p9 and HIV-1 p6 have several functions in common. Interestingly, these two functionally analogous proteins possess quite different biochemical and biophysical properties i.e. primary sequence, hydrophilicity and net charge, which would be expected to lead to different protein-protein interactions in the respective host cell system. Both proteins possess little sequence homology (only ~7% identity) and are predicted to differ significantly in their phosphorylation propensities. HIV-1 p6 was characterized as a largely phosphorylated protein . Similarly, both molecules have two ubiquitinylation sites and were shown to become mono-ubiquitinylated, and in the case of p6, sumoylated, Fig. 1[29–31].
The L-domains of p9 and p6, as well as similar domains from other viral systems, have received considerable attention as they play critical roles in controlling the interaction with the host system that finally promotes viral budding and particle release [5–7]. These interactions involve the binding of specific regions of each molecule with components of the ESCRT [11, 12]. Of particular relevance is the well-defined interaction of both molecules with ALIX, an ESCRT associated, multifunctional protein that interacts with both ESCRT-I and ESCRT-III. The ALIX-binding motif in both molecules responsible for this interaction has been defined recently as (L) [FY]PX1-3LXX [IL] [32–34] and corresponds in our case to 22LYP DL SEI in p9 and 35LYPLASL RSL in p6 in which essential residues are in bold. Recently, the structure of ALIX has been worked out in detail [16, 32, 35] and its interaction with p6 was modeled based on NMR data of p6 . In this model the C-terminal helix found in hydrophobic environments aligns coaxially with three helices in the ALIX V domain long arm to form a four-helix bundle . The presence of a similar helical motif in the C-terminus of p9 presumably affords the same binding interaction. It is important to note that the ALIX-binding domain of p6 is located within the helical region of the molecule while in p9 it is located in a partially unstructured region.
The structural investigations on p6 and p9 offer a rationale for the different spacing of the essential residues in the ALIX-binding domains pointed out by Munshi et al. . During ALIX binding hydrophobic conditions pertain and both molecules will adopt their most structured conformations. In p9 the ALIX-binding domain 22LYPDL27SEI motif is at the junction of an unstructured and beginning of the helical region (Ser-27) of the molecule in this conformation (Fig. 7 and 8), while in p6 the whole 35LYPLASLRSL motif is found within the helical region under the same conditions, Fig. 8. In this helical conformation the essential lysine residue at position 42 in p6 is brought into the proximity of the 3 amino acid sequence LYP through the introduction of one helix turn, the intervening two residues are now on the opposite side of the helix away from the hydrophobic interaction site of the ALIX V domain . This re-arranged recognition site of adjacent residues 35LYP 40SLRSL now imitates the ALIX motif LYPDLSEI of p9. Thus, the helical conformation in p6 is required to position the essential residues correctly and maintain the ALIX-p6 functional interaction by re-orienting the 39LA residues to the other side of helix away from the interaction site, while this is not necessary for p9. In addition, the C-terminal helix of p9 is substantially longer than the corresponding helix in p6 (Fig. 8) and thereby has a larger surface for potential interaction with the ALIX V domain. These structural differences in the ALIX-binding domains of the two molecules are reflected in the considerably higher thermodynamic stability of the p9-ALIX complexes [32, 34] suggesting p9 has an optimized ALIX-binding site compared to that of p6 .
Recently, the X-ray structures of the complexes of ALIX with short synthetic peptides corresponding to the L-domains of HIV-1 p6 and EIAV p9 have been elucidated . In these studies, the conserved tyrosine residue of the L-domains plays a crucial role in positioning the peptides in the same hydrophobic groove of arm 2 of the ALIX V domain. In keeping with our analysis of the solution structures an extra helical turn is observed in the crystal structure of p6 to position Leu-42 in the same position as Leu-26 in p9. These structures also define the orientation of the peptide chains and indicate the ALIX V domain is able to accommodate the short peptides without any major helical movements between the free and bound forms. According to our solution data the C-terminal helical region of both p6 and p9 could be accommodated towards the open neck of the ALIX V domain  while the flexible N-termini would allow these to be accommodated in the loop region. It remains to be determined whether these interactions of the full length proteins in the context of the uncleaved Gag polyprotein cause unfolding of ALIX.
Until recently the L-domains of p9 and p6 have usually been defined as those regions containing the YPDL and PT/SAP motifs, respectively [5–7]. Clearly this implies the ALIX-binding domain and L-domain motifs overlap (or are identical) in p9, but are separated in p6 where the L-domain is positioned proximal to the PTAP motif, Fig. 8.
For p6, the PTAP L-domain binds to Tsg101, the human equivalent of Vps23 of the yeast ESCRT-I complex that has recently been completely defined structurally . Currently, there is no evidence of an equivalent interaction for p9. Indeed, the optimized ALIX binding site in p9 implies EIAV requires only a single L-domain for budding while the suboptimal binding site found in p6 requires the presence of a second site that functions through binding to Tsg101. This is corroborated by sequence data for p6 derived from different SIV strains where those containing high affinity ALIX binding sites do not have a Tsg101 binding site and vice versa .
Thus, it can be argued that the YPDL L-domain of EIAV does not require an independent ESCRT-I interaction [37, 38] as the interactions between ESCRT-I and ESCRT-III are bridged through an appropriate conformation of ALIX stabilized by the strong interaction of p9. Presumably, in this bound form the N-terminal domain of ALIX binds to the ESCRT-III complex while the C-terminal proline-rich region binds the Tsg101 binding domain of ESCRT-I.
In summary, p9 from EIAV, like p6 from HIV-1, is structurally very labile and can exist in a number of conformational states that depend on its environment and the presence of binding partners that interact with specific domains in the molecule.
Although p9 and p6 are sequentially quite different, both possess C-terminal helical structures in their most structured states that must be present during binding to the hydrophobic pocket of ALIX, a central control node in viral budding. Differences in the structural features in the vicinity of the ALIX-binding motif correlate with the different binding properties of the molecules and with the requirement of a further L-domain found only in p6 in the weakly structured N-terminal domain.
Peptides and protein
The sequence of full length p9 and its two fragments, p91-21 and p922-51, used in this study is that derived from the isolate EIAVWYOMING, Fig. 1 (16).
Peptide synthesis, purification, and characterization
The syntheses of the full length peptide were performed on an ABI 433A automated peptide synthesizer (Applied Biosystems, Darmstadt, Germany) on a 0.1 mM scale with 300 mg TentaGel S-Trt-Glu(tBu)-Fmoc-resin (capacity 0.17 mmol/g; RAPP Polymere GmbH Tübingen, Germany) using the Fmoc (N-(9-fluorenyl)methoxycarbonyl)/t-butyl strategy. The following side-chain protecting groups were used: t-butyloxycarbonyl (Trp, Lys), t-butyl ether (Thr, Ser, Tyr), t-butyl ester (Asp, Glu) and trityl (Asn, Gln and His). Couplings were performed with N- [1H-7-aza-benzotriazol(1-yl)(dimethylamino)-methylene]-N-methylmethanaminium hexafluoro-phosphate-N-oxide in N-methylpyrrolidone as coupling agent. Amino acids in positions 10 and 11 (Lys-Ser) were introduced as the pseudoproline derivative Fmoc-Lys(Boc)-Ser(ΨMe, Me Pro)-OH. Deprotection of the Fmoc group was performed during the complete synthesis with 20% piperidine in N,N-dimethylformamide. The final cleavage from the resin was performed with 95% TFA in water containing 3% triisopropylsilane and 5% phenol. The crude protein was purified by reversed phase HPLC (RP-HPLC) on a 7 μ Zorbax SB C18 column (21.2 × 250 mm) with a linear gradient of 50% B to 60% B in 45 min (A: 2500 ml water, 5 ml TFA; B: 2000 ml acetonitrile, 500 ml water, 5 ml TFA) at a flow rate of 10 ml/min with spectrophotometric monitoring at λ = 220 nm. The fractions were checked by RP-HPLC (Shimadzu LC10) on a Nulceosil C 18 column (4.6 × 125 mm, 5 μ, 300 Å) with a linear gradient of 10% B to 100% B over 45 min to give the final pure products. The fragments s p91-21 and s p922-51 were synthesized and purified in the same manner. The full length synthetic protein and the N- and C-terminal peptides are designated as s p9, s p91-21 and s p922-51, respectively.
Peptide sequencing and mass spectrometry
For s p9, the sequencing steps were completed on an Applied Biosystems 473A pulsed liquid phase sequencer according to a standard protocol. Positive ion ESI mass spectra were recorded on a Micromass Q-Tof-2™ mass spectrometer. Samples were dissolved in 70% aqueous methanol and infused at a flow rate of ca. 1 μl/min at ca. 0.8 kv needle voltage into the electrospray chamber The experimental spectra showing multiply charged molecular ions were deconvoluted with standard software. MALDI/TOF mass spectra were recorded on a Bruker reflex MALDI/TOF mass spectrometer using an N2 laser (337 nm) (see additional file 1).
Circular dichroism (CD) spectroscopy
CD spectra of the protein samples of full-length s p9 and its related shorter fragments s p91-21 and s p922-51were recorded at room temperature and a concentration of 0.2 mg ml-1 in 0.5 mm cuvettes on a Jasco J-810 spectropolarimeter in a wavelength range from 260 to 180 nm at various pH values and trifluoroethanol (TFE) concentrations as described previously . The resulting curves were smoothed using a high frequency filter, and secondary structure elements were quantified by deconvoluting the measured ellipticity using the DICROPROT 2000 program .
1H NMR spectroscopy
All one- (1D) and two-dimensional (2D) 1H NMR spectra of s p9 and its fragments s p91-21 and s p922-51 were recorded with (1D) or without (2D) spinning at 300 K on a Bruker Avance DMX 600 MHz instrument using a triple resonance probe head with gradient unit. The peptides were dissolved without pH adjustment (pH ~3.0) to final concentrations of 2-3 mM in 1:1 mixtures of H2O and CF3CD2OH (50% aqueous TFE-d2). Measurements were carried out with mixing times of 110 ms for the 2D TOCSY and 500 ms for the 2D NOESY experiments, respectively. Data acquisition, processing and spectral analysis were in all cases performed with standard Bruker software. All spectra were internally referenced to the residual TFE-H2 methylene signal at 3.95 ppm. The unambiguous amino acid spin systems and the sequential assignments (see additional file 1) were established using a standard procedure . The complete signal assignments and 1H chemical shifts of s p922-51 have been deposited in the Biological Magnetic Resonance Data Bank under accession number RCSB100795.
The structure of s p922-51 was determined from quantitative NOE data as described in detail elsewhere . Structures were calculated on a Silicon Graphics Octane work station using the program CNS 1.0 with standard CNS parameters for protein data sets . A total of 346 distance restraints were used to generate 100 conformations of which 20 conformations, exhibiting no restraint violations greater than 0.2 Å and having the lowest energy values, were used for the final fitting analysis.
The heterogeneity within the final set of 20 structures was visualized using the consecutive segment approach which allows fitting regions for alignments to be defined (19). The central structure showing the lowest root mean square deviation (rmsd) of its fitting region to those of the other structures was then determined using the programs LSQMAN and MOLEMAN2 (Uppsala Software Factory) . Finally, alignments were performed by superimposing the fitting regions of all other structures to that of the central structure and these were visualized with the PYMOL program http://www.pymol.org. The final structure of s p922-51 has been deposited in the Protein Data Bank under code PDBID 2K84.
In this study the probability for helical or extended conformation of dipeptidic segments in the full length s p9 molecule was analyzed using the distances between 1H nuclei of adjacent residues, namely HN and Hα of residue i and HN of residue i+1 (dNN(i, i+1), dαN(i, i+1)) (22). The distances d which strictly correlate with signal intensities I (I ~1/d6) were obtained by transferring the intensities of the respective NOE signals into interproton distances using the Bruker program AURELIA. Only unambiguous signals were used for this analysis. For a few signals that were weakened by the pre-saturation of the water resonance a correction was applied (-1.5 Å when within 0.005 ppm of the water signal, -1 Å when within 0.025 ppm, and -0.5 Å when within 0.05 ppm), and a similar correction was made in cases where two or more signals could not be resolved individually due to close signal overlap. An equation given by Bradley et al.  was then used to calculate probabilities for helical or extended conformations.
This work was supported by grant IE-S08T06 from the German Human Genome Research Project, by grant from the BioMedTec International Graduate School of Science, by grant from the FORINGEN research network, funded by the State of Bavaria, Germany, and by grants SCHU 1125/5-1 and SCHU1125/3 from the German Research Council to US. We thank Christel Kakoschke and Prisca Kunert for technical assistance, Dr. Manfred Nimtz for mass spectrometric analyses, Dr. Birgit Hoffmann for help with the structural calculations.
- Henderson LE, Sowder RC, Smythers GW, Oroszlan S: Chemical and immunological characterizations of equine infectious anemia virus gag-encoded proteins. J Virol 1987, 61: 1116–1124.PubMed CentralPubMedGoogle Scholar
- Montelaro RC, Lohrey N, Parekh B, Blakeney EW, Issel CJ: Isolation and comparative biochemical properties of the major internal polypeptides of equine infectious anemia virus. J Virol 1982, 42: 1029–1038.PubMed CentralPubMedGoogle Scholar
- Vogt VM, Eisenman R, Diggelmann H: Generation of avian myeloblastosis virus structural proteins by proteolytic cleavage of a precursor polypeptide. J Mol Biol 1975, 96: 471–493. 10.1016/0022-2836(75)90174-6View ArticlePubMedGoogle Scholar
- Jin S, Chen C, Montelaro RC: Equine infectious anemia virus Gag p9 function in early steps of virus infection and provirus production. J Virol 2005, 79: 8793–8801. 10.1128/JVI.79.14.8793-8801.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Demirov DG, Freed EO: Retrovirus budding. Virus Res 2004, 106: 87–102. 10.1016/j.virusres.2004.08.007View ArticlePubMedGoogle Scholar
- Bieniasz PD: Late budding domains and host proteins in enveloped virus release. Virology 2006, 344: 55–63. 10.1016/j.virol.2005.09.044View ArticlePubMedGoogle Scholar
- Martin-Serrano J: The Role of Ubiquitin in Retroviral Egress. Traffic 2007, 8: 1297–1303. 10.1111/j.1600-0854.2007.00609.xView ArticlePubMedGoogle Scholar
- VerPlank L, Bouamr F, LaGrassa TJ, Agresta B, Kikonyogo A, Leis J, Carter CA: Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci USA 2001, 98: 7724–7729. 10.1073/pnas.131059198PubMed CentralView ArticlePubMedGoogle Scholar
- Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Cote M, Rich RL, et al.: Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001, 107: 55–65. 10.1016/S0092-8674(01)00506-2View ArticlePubMedGoogle Scholar
- Williams RL, Urbe S: The emerging shape of the ESCRT machinery. Nat Rev Mol Cell Biol 2007, 8: 355–368. 10.1038/nrm2162View ArticlePubMedGoogle Scholar
- Carlton JG, Agromayor M, Martin-Serrano J: Differential requirements for Alix and ESCRT-III in cytokinesis and HIV-1 release. Proc Natl Acad Sci USA 2008, 105: 10541–10546. 10.1073/pnas.0802008105PubMed CentralView ArticlePubMedGoogle Scholar
- Carlton JG, Martin-Serrano J: Parallels between cytokinesis and retroviral budding: a role for the ESCRT machinery. Science 2007, 316: 1908–1912. 10.1126/science.1143422View ArticlePubMedGoogle Scholar
- Puffer BA, Parent LJ, Wills JW, Montelaro RC: Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein. J Virol 1997, 71: 6541–6546.PubMed CentralPubMedGoogle Scholar
- Li F, Chen C, Puffer BA, Montelaro RC: Functional replacement and positional dependence of homologous and heterologous L domains in equine infectious anemia virus replication. J Virol 2002, 76: 1569–1577. 10.1128/JVI.76.4.1569-1577.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Fossen T, Wray V, Bruns K, Rachmat J, Henklein P, Tessmer U, Maczurek A, Klinger P, Schubert U: Solution structure of the human immunodeficiency virus type 1 p6 protein. J Biol Chem 2005, 280: 42515–42527. 10.1074/jbc.M507375200View ArticlePubMedGoogle Scholar
- Lee S, Joshi A, Nagashima K, Freed EO, Hurley JH: Structural basis for viral late-domain binding to Alix. Nat Struct Mol Biol 2007, 14: 194–199. 10.1038/nsmb1203PubMed CentralView ArticlePubMedGoogle Scholar
- Pornillos O, Alam SL, Davis DR, Sundquist WI: Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Nat Struct Biol 2002, 9: 812–817.PubMedGoogle Scholar
- Luidens MK, Figge J, Breese K, Vajda S: Predicted and trifluoroethanol-induced alpha-helicity of polypeptides. Biopolymers 1996, 39: 367–376. Publisher Full Text 10.1002/(SICI)1097-0282(199609)39:3<367::AID-BIP8>3.0.CO;2-MView ArticlePubMedGoogle Scholar
- Wishart DS, Sykes BD, Richards FM: The chemical shift index: a fast and simple method for the assignment of protein secondary structure through NMR spectroscopy. Biochemistry 1992, 31: 1647–1651. 10.1021/bi00121a010View ArticlePubMedGoogle Scholar
- Wüthrich K: NMR of Proteins and Nucleic Acids. New York: John Wiley & Sons, Inc; 1986.Google Scholar
- Votteler J, Studtrucker N, Sorgel S, Munch J, Rucker E, Kirchhoff F, Schick B, Henklein P, Fossen T, Bruns K, et al.: Proline 35 of human immunodeficiency virus type 1 (HIV-1) Vpr regulates the integrity of the N-terminal helix and the incorporation of Vpr into virus particles and supports the replication of R5-tropic HIV-1 in human lymphoid tissue ex vivo. J Virol 2007, 81: 9572–9576. 10.1128/JVI.02803-06PubMed CentralView ArticlePubMedGoogle Scholar
- Bruns K, Fossen T, Wray V, Henklein P, Tessmer U, Schubert U: Structural characterization of the HIV-1 Vpr N terminus: evidence of cis/trans-proline isomerism. J Biol Chem 2003, 278: 43188–43201. 10.1074/jbc.M305413200View ArticlePubMedGoogle Scholar
- Bradley EK, Thomason JF, Cohen FE, Kosen PA, Kuntz ID: Studies of synthetic helical peptides using circular dichroism and nuclear magnetic resonance. J Mol Biol 1990, 215: 607–622. 10.1016/S0022-2836(05)80172-XView ArticlePubMedGoogle Scholar
- Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, et al.: Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998, 54: 905–921. 10.1107/S0907444998003254View ArticlePubMedGoogle Scholar
- Blankenfeldt W, Nokihara K, Naruse S, Lessel U, Schomburg D, Wray V: NMR spectroscopic evidence that helodermin, unlike other members of the secretin/VIP family of peptides, is substantially structured in water. Biochemistry 1996, 35: 5955–5962. 10.1021/bi9601520View ArticlePubMedGoogle Scholar
- Kleywegt GJ: Use of non-crystallographic symmetry in protein structure refinement. Acta Crystallogr D Biol Crystallogr 1996, 52: 842–857. 10.1107/S0907444995016477View ArticlePubMedGoogle Scholar
- Stys D, Blaha I, Strop P: Structural and functional studies in vitro on the p6 protein from the HIV-1 gag open reading frame. Biochim Biophys Acta 1993, 1182: 157–161.View ArticlePubMedGoogle Scholar
- Müller B, Patschinsky T, Kräusslich HG: The late-domain-containing protein p6 is the predominant phosphoprotein of human immunodeficiency virus type 1 particles. J Virol 2002, 76: 1015–1024.PubMed CentralView ArticlePubMedGoogle Scholar
- Gurer C, Berthoux L, Luban J: Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J Virol 2005, 79: 910–917. 10.1128/JVI.79.2.910-917.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Ott DE, Coren LV, Chertova EN, Gagliardi TD, Schubert U: Ubiquitination of HIV-1 and MuLV Gag. Virology 2000, 278: 111–121. 10.1006/viro.2000.0648View ArticlePubMedGoogle Scholar
- Ott DE, Coren LV, Sowder RC, Adams J, Nagashima K, Schubert U: Equine infectious anemia virus and the ubiquitin-proteasome system. J Virol 2002, 76: 3038–3044. 10.1128/JVI.76.6.3038-3044.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Fisher RD, Chung HY, Zhai Q, Robinson H, Sundquist WI, Hill CP: Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding. Cell 2007, 128: 841–852. 10.1016/j.cell.2007.01.035View ArticlePubMedGoogle Scholar
- Munshi UM, Kim J, Nagashima K, Hurley JH, Freed EO: An Alix fragment potently inhibits HIV-1 budding: characterization of binding to retroviral YPXL late domains. J Biol Chem 2007, 282: 3847–3855. 10.1074/jbc.M607489200View ArticlePubMedGoogle Scholar
- Zhai Q, Fisher RD, Chung HY, Myszka DG, Sundquist WI, Hill CP: Structural and functional studies of ALIX interactions with YPX(n)L late domains of HIV-1 and EIAV. Nat Struct Mol Biol 2008, 15: 43–49. 10.1038/nsmb1319View ArticlePubMedGoogle Scholar
- Kostelansky MS, Schluter C, Tam YY, Lee S, Ghirlando R, Beach B, Conibear E, Hurley JH: Molecular architecture and functional model of the complete yeast ESCRT-I heterotetramer. Cell 2007, 129: 485–498. 10.1016/j.cell.2007.03.016PubMed CentralView ArticlePubMedGoogle Scholar
- Bibollet-Ruche F, Bailes E, Gao F, Pourrut X, Barlow KL, Clewley JP, Mwenda JM, Langat DK, Chege GK, McClure HM, et al.: New simian immunodeficiency virus infecting De Brazza's monkeys (Cercopithecus neglectus): evidence for a cercopithecus monkey virus clade. J Virol 2004, 78: 7748–7762. 10.1128/JVI.78.14.7748-7762.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Martin-Serrano J, Yarovoy A, Perez-Caballero D, Bieniasz PD: Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. Proc Natl Acad Sci USA 2003, 100: 12414–12419. 10.1073/pnas.2133846100PubMed CentralView ArticlePubMedGoogle Scholar
- Strack B, Calistri A, Craig S, Popova E, Göttlinger HG: AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 2003, 114: 689–699. 10.1016/S0092-8674(03)00653-6View ArticlePubMedGoogle Scholar
- Viseu MI, Carvalho TI, Costa SM: Conformational transitions in beta-lactoglobulin induced by cationic amphiphiles: equilibrium studies. Biophys J 2004, 86: 2392–2402. 10.1016/S0006-3495(04)74296-4PubMed CentralView ArticlePubMedGoogle Scholar
- Karplus K, Barrett C, Hughey R: Hidden Markov models for detecting remote protein homologies. Bioinformatics 1998, 14: 846–856. 10.1093/bioinformatics/14.10.846View ArticlePubMedGoogle Scholar
- Pollastri G, Przybylski D, Rost B, Baldi P: Improving the prediction of protein secondary structure in three and eight classes using recurrent neural networks and profiles. Proteins 2002, 47: 228–235. 10.1002/prot.10082View ArticlePubMedGoogle Scholar
- Baldi P, Brunak S, Frasconi P, Soda G, Pollastri G: Exploiting the past and the future in protein secondary structure prediction. Bioinformatics 1999, 15: 937–946. 10.1093/bioinformatics/15.11.937View ArticlePubMedGoogle Scholar
- Pollastri G, McLysaght A: Porter: a new, accurate server for protein secondary structure prediction. Bioinformatics 2005, 21: 1719–1720. 10.1093/bioinformatics/bti203View ArticlePubMedGoogle Scholar
- McGuffin LJ, Bryson K, Jones DT: The PSIPRED protein structure prediction server. Bioinformatics 2000, 16: 404–405. 10.1093/bioinformatics/16.4.404View ArticlePubMedGoogle Scholar
- Rost B, Sander C: Prediction of protein secondary structure at better than 70% accuracy. J Mol Biol 1993, 232: 584–599. 10.1006/jmbi.1993.1413View ArticlePubMedGoogle Scholar
- Rost B, Sander C, Schneider R: PHD--an automatic mail server for protein secondary structure prediction. Comput Appl Biosci 1994, 10: 53–60.PubMedGoogle Scholar
- Garnier J, Osguthorpe DJ, Robson B: Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. J Mol Biol 1978, 120: 97–120. 10.1016/0022-2836(78)90297-8View ArticlePubMedGoogle Scholar
- Garnier J, Gibrat JF, Robson B: GOR method for predicting protein secondary structure from amino acid sequence. Methods Enzymol 1996, 266: 540–553. full_textView ArticlePubMedGoogle Scholar
- Guermeur Y, Geourjon C, Gallinari P, Deleage G: Improved performance in protein secondary structure prediction by inhomogeneous score combination. Bioinformatics 1999, 15: 413–421. 10.1093/bioinformatics/15.5.413View ArticlePubMedGoogle Scholar
- Geourjon C, Deleage G: SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments. Comput Appl Biosci 1995, 11: 681–684.PubMedGoogle Scholar
- Sen TZ, Jernigan RL, Garnier J, Kloczkowski A: GOR V server for protein secondary structure prediction. Bioinformatics 2005, 21: 2787–2788. 10.1093/bioinformatics/bti408PubMed CentralView ArticlePubMedGoogle Scholar
- Kloczkowski A, Ting KL, Jernigan RL, Garnier J: Combining the GOR V algorithm with evolutionary information for protein secondary structure prediction from amino acid sequence. Proteins 2002, 49: 154–166. 10.1002/prot.10181View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.